Journal
TRANSPLANTATION PROCEEDINGS
Volume 40, Issue 5, Pages 1237-1248Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2008.04.003
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01 HL063442-01A2, 5R01 HL063442, R01 HL063442] Funding Source: Medline
- NIDDK NIH HHS [R01 DK069766-01A1, R01 DK069766] Funding Source: Medline
Ask authors/readers for more resources
Composite tissue allotransplantation (CTA) is emerging as a potential treatment for complex tissue defects. It is currently being performed with increasing frequency in the clinic. The feasibility of the procedure has been confirmed through 30 hand transplantation, 3 facial reconstructions, and vascularized knee, esophageal, and tracheal allografts. A major drawback for CTA is the requirement for lifelong immunosuppression. The toxicity of these agents has limited the widespread application of CTA. Methods to reduce or eliminate the requirement for immunosuppression and promote CTA acceptance would represent a significant step forward in the field. Multiple studies suggest that mixed chimerism established by bone marrow transplantation promotes tolerance resulting in allograft acceptance. This overview focuses on the history and the exponentially expanding applications of the new frontier in CTA transplantation: immunology associated with CTA; preclinical animal models of CTA; clinical experience with CTA; and advances in mixed chimerism-induced tolerance in CTA. Additionally, some important hurdles that must be overcome in using bone marrow chimerism to induce tolerance to CTA are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available